Serine Protease 3 Promotes Progression of Diffuse Large B-Cell Lymphoma and Serves as a Novel Prognostic Predictor

Table 3

Multivariate analysis.

Variables	HR	95% CI	value
Age (>60 vs. ≤60 yrs)	1.778	1.101-2.871	0.019
B symptoms (presence vs. absence)	2.565	1.543-4.262	<0.001
Ann Arbor stage (III-IV vs. I-II)	2.520	1.505-4.218	<0.001
ECOG PS (≥2 vs. 0-1)	1.924	1.089-3.398	0.024
Serum LDH level (elevated vs. normal)	1.871	1.125-3.111	0.016
ENI (≥2 vs. <2)	1.435	0.854-2.411	0.172
IPI (3-5 vs. 0-2)	3.435	1.918-6.151	<0.001
COO (ABC vs. GCB)	1.699	1.047-2.757	0.032
PRSS3 protein level (high vs. low)	1.807	1.040-3.138	0.036

Abbreviations: PRSS3: serine protease 3; ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: lactate dehydrogenase; ENI: extra nodal involvement; IPI: International Prognostic Index; COO: cell-of-origin; GCB: germinal center B cell; ABC: activated B cell.